HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quin, J D Articles by Miell, J P Search for Related Content PubMed PubMed Citation Articles by Quin, J D Articles by Miell, J P

It has been suggested that recombinant human IGF-I (rhIGF-I) is a potential therapeutic agent in diabetes mellitus. It is known to have glucose-lowering effects in normal individuals, in patients with non-insulindependent diabetes (NIDDM) and in extreme insulin-resistant states. IGF-binding proteins (IGFBPs) have the potential to affect the biological activity of rhIGF-I. We have studied the effect of infused rhIGF-I on IGFBP-1 and IGFBP-3 in a patient with Mendenhall's syndrome, a rare insulin-resistant state. During an infusion of 20 mg rhIGF-I, glucose concentrations fell from 44·1 ±7·2 to 31·5 ±7·2 (S.E.M.) mmol/l (P=0·001), and insulin and C-peptide levels fell from 920 ±62 to 542±45 mU/l (P=0·008) and 5466 ±633 to 3071 ±297 pmol/l (P= 0·02) respectively. Significant lowering of phosphate, magnesium and alkaline phosphatase concentrations was also noted. IGF-I levels rose from 48 ±10·2 to 410 ±50·1 µg/l (P=0·001), and those of IGF-II fell from 279·8± 8·3 to 104·3 ±7·9 µg/l (P=0·001). IGFBP-1 concentrations did not significantly change during the infusion but those of IGFBP-3 increased from 1655 ± 127 to 2197 ± 334 µg/l (P=0·002), despite a significant fall in GH concentrations from 10·7±2·6 to 4·1±1·1 mU/l (P= 0·007), suggesting that IGFBP-3 regulation is also IGF-I-dependent. The lack of response of IGFBP-1 to a significant fall in insulin levels suggests that impaired insulin receptor function alters the usual regulation of IGFBP-1 by insulin. These findings are of importance, given the potential use of rhIGF-I in NIDDM.

Journal of Endocrinology (1994) 141, 177–182

This article has been cited by other articles:

				R. V. Bhat, T. M. Engber, Y. Zhu, M. S. Miller, and P. C. Contreras Identification of Insulin-Like Growth Factor Binding Protein-2 as a Biochemical Surrogate Marker for the in Vivo Effects of Recombinant Human Insulin-Like Growth Factor-1 in Mice J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 522 - 530. [Abstract] [Full Text]